Literature DB >> 11095979

Genomic organization and transcriptional regulation of human Apo2/TRAIL gene.

B Gong1, A Almasan.   

Abstract

Apo2L, or TRAIL, is a type II integral membrane protein belonging to the TNF family which induces apoptotic cell death in a variety of human tumor cells. Apo2L is expressed in many tissues, suggesting that it is nontoxic to normal cells. We found that Apo2L mRNA was induced by interferon (IFN)-alpha and -beta, but not -gamma, in Jurkat cells. To gain a better understanding of the molecular mechanisms that regulate expression of Apo2L, we have characterized the organization of the human Apo2L gene and its promoter region. The Apo2L gene spans approximately 20 kb and is composed of five exons. The 1.2-kb Apo2L promoter region upstream of the translation initiation codon was cloned, its transcription start site defined, and several putative transcription factor binding sites identified. Luciferase reporter constructs were transfected into Jurkat cells and shown to be induced by IFNs. Deletion analysis indicates that the Apo2L promoter region between nucleotides 126 and 33 upstream of the transcriptional start site controls the expression of the Apo2L gene following IFN-beta treatment. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095979     DOI: 10.1006/bbrc.2000.3872

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  Anticancer activity of a cyclooxygenase inhibitor, CX9051, in human prostate cancer cells: the roles of NF-kappaB and crosstalk between the extrinsic and intrinsic apoptotic pathways.

Authors:  Chiung-Hua Huang; Jih-Hwa Guh; Grace Shiahuy Chen; Pin-Hsuan Lu; Ji-Wang Chern
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-06-08       Impact factor: 3.000

2.  Identification of TRAIL as an interferon regulatory factor 3 transcriptional target.

Authors:  Jessica R Kirshner; Alla Y Karpova; Maren Kops; Peter M Howley
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 3.  Major apoptotic mechanisms and genes involved in apoptosis.

Authors:  Yağmur Kiraz; Aysun Adan; Melis Kartal Yandim; Yusuf Baran
Journal:  Tumour Biol       Date:  2016-04-09

4.  TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.

Authors:  Sekar Natesampillai; Ana C Paim; Nathan W Cummins; Aswath P Chandrasekar; Gary D Bren; Sharon R Lewin; Hans-Peter Kiem; Andrew D Badley
Journal:  J Immunol       Date:  2019-06-12       Impact factor: 5.422

Review 5.  Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.

Authors:  Xiaoyun Dai; Jingwen Zhang; Frank Arfuso; Arunachalam Chinnathambi; M E Zayed; Sulaiman Ali Alharbi; Alan Prem Kumar; Kwang Seok Ahn; Gautam Sethi
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-07

Review 6.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

7.  Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL.

Authors:  Nicole Clarke; Ana M Jimenez-Lara; Emilie Voltz; Hinrich Gronemeyer
Journal:  EMBO J       Date:  2004-07-08       Impact factor: 11.598

Review 8.  Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma.

Authors:  Quan Chen; Subrata Ray; Mohamad A Hussein; Gordan Srkalovic; Alexandru Almasan
Journal:  Leuk Lymphoma       Date:  2003-07

9.  Sp1-mediated TRAIL induction in chemosensitization.

Authors:  Jing Xu; Jun-Ying Zhou; Wei-Zen Wei; Sjaak Philipsen; Gen Sheng Wu
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

10.  Type I interferons and interferon regulatory factors regulate TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected macrophages.

Authors:  Yunlong Huang; Angelique Walstrom; Luwen Zhang; Yong Zhao; Min Cui; Ling Ye; Jialin C Zheng
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.